Akorn to Present at the RBC Capital Markets Healthcare Conference
May 20 2019 - 8:01AM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that management will
present at the 2019 RBC Capital Markets Healthcare Conference on
Wednesday, May 22, 2019 at 2:05 p.m. EDT in New York, NY. A live
webcast of the presentation can be accessed on the investor page of
Akorn's website at http://investors.akorn.com. A replay of the
webcast will also be available for 90 days on Akorn's website
following the conference.
Cautionary Note Regarding
Forward-Looking Statements The webcast may include
forward-looking statements about, among other things, the Company’s
business plans and initiatives, the Company’s commitments to the
FDA and remediation efforts, disruptions during the Standstill
Period, the Company’s anticipated future operating and financial
performance, business plans and prospects, product pipeline,
including filings, approvals and launches, capital allocation, debt
refinancing, and potential dispositions, that are subject to
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. These risk factors include, but are not limited to: (i)
the effect of the Delaware court’s recent decision against the
Company on the Company’s ability to retain and hire key personnel,
its ability to maintain relationships with its customers, suppliers
and others with whom it does business, or its operating results and
business generally, (ii) the risk that ongoing or future litigation
related to the court’s decision may result in significant costs of
defense, indemnification and/or liability, (iii) the outcome of the
investigation conducted by the Company with the assistance of
outside consultants, into alleged breaches of FDA data integrity
requirements relating to product development at the Company and any
actions taken by the Company, third parties or the FDA as a result
of such investigations, (iv) the difficulty of predicting the
timing or outcome of product development efforts, including FDA and
other regulatory agency approvals and actions, if any, (v) the
timing and success of product launches, (vi) difficulties or delays
in manufacturing, (vii) the Company’s increased indebtedness and
compliance with certain covenants and other obligations under the
Standstill Agreement, which create material uncertainties and risks
to its growth and business outlook, (viii) the Company’s obligation
under the Standstill Agreement to enter into a Comprehensive
Amendment that is satisfactory in form and substance to the
Lenders, (ix) the Company’s obligation under the Standstill
Agreement to pay certain fees and expenses and increased interest
margin, (x) such other risks and uncertainties outlined in the risk
factors detailed in Part I, Item 1A, “Risk Factors,” of the
Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 (as filed with the Securities and Exchange
Commission (“SEC”) on March 1, 2019), to be detailed in Part II,
Item 1A, “Risk Factors,” of the Company’s Quarterly Report on Form
10-Q for the fiscal quarter ended March 31, 2019 (filed with the
SEC on May 7, 2019) and other risk factors identified from time to
time in the Company’s subsequent reports on Form 8-K and in other
Company filings with the SEC. Readers should carefully review these
risk factors, and should not place undue reliance on the Company’s
forward-looking statements. These forward-looking statements are
based on information, plans and estimates at the date of this
report. The Company undertakes no obligation to update any
forward-looking statements to reflect changes in underlying
assumptions or factors, new information, future events or other
changes. The forward-looking statements in the webcast speak only
as of the original date of the webcast. Akorn assumes no obligation
to update forward-looking statements contained in the webcast as
the result of new information or future events or developments.
About AkornAkorn, Inc. is a specialty
generic pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website at www.akorn.com.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Apr 2023 to Apr 2024